Sign up USA
Proactive Investors - Run By Investors For Investors
Why invest in AVO?
Advanced Oncotherapy PLC: THE INVESTMENT CASE
INVESTMENT OVERVIEW

Advanced Oncotherapy’s LIGHT system has “fast head start” on changing cancer treatment market, says broker goetzpartners

The broker says the cancer treatment developer could potentially take the entire share of the growth market from ageing cyclotron companies
Proton Therapy sign
INVESTMENT OVERVIEW: AVO The Big Picture
The broker says the LIGHT system is “faster and less complicated" than cyclotron technology

Advanced Oncotherapy PLC (LON:AVO), which is developing a breakthrough new proton therapy system for cancer sufferers, could have a “fast head-start” in the race to replace other forms of treatment in the market, according to analysts at broker goetzpartners.

In a note to clients, the broker said that the company’s proton beam treatment system, known as Linac Image Guided Hadron Technology (LIGHT), could help it take “the entire growth” from its cyclotron competitors, a technology that will become obsolete by the end of 2023.

Cyclotron technology involves lengthy and complicated building preparation, with heavy cyclotrons and large concrete bunkers make the installation a major building project, which is, regardless of pricing, often a big hurdle.

However, the broker says the LIGHT system, which is “faster and less complicated combined with a cheaper production process”, could give the company a step up against both cyclotrons and more conventional LINAC (linear accelerator) systems.

The proton therapy industry, in which AVO operates, offers “significant structural growth”, goetz said, with its own numbers forecasting a US$8bn market by the end of 2030.

LIGHT tech backed by world-leading physicists

AVO’s beam technology is currently being worked on by the team at ADAM, a spin-off from renowned Swiss physics lab CERN, which includes some of the world leading physicists.

The firm recently announced that it had successfully integrated the four sections of its LIGHT proton accelerator, the proton source, the Radiofrequency Quadrupole (RFQ), four Side Coupled Drift Tube Linacs (SCDTLs), and two high-energy accelerating structures, the Coupled Cavity Linacs (CCLs), at the lab and had achieved an energy of 52 mega-electron volts (MeV), double the amount needed to treat superficial cancer tumours.

READ: Advanced Oncotherapy rockets as it improves performance of LIGHT cancer treatment system

However, the company isn’t stopping and is aiming to add 13 more CCL modules which would increase the energy level to 230MeV, the level required to treat deep-seated tumours.

goetzpartners expects the company to achieve this energy level in 2019, adding that they saw “limited” risks to the set up of the company’s LIGHT system for its first customer at a clinic in Harley Street, the renowned private medical district in London.

First player in ‘holistic’ oncology process

AVO’s partnership with Swedish radiotherapy software firm, RaySearch, also gives it a potential first-mover advantage in developing “a fully integrated and holistic oncology treatment process”, says goetz.

The broker says that the combination of the LIGHT system and RaySearch’s treatment planning and oncology information systems would go “far beyond an optimal use of proton therapy systems”.

goetzpartners has Advanced Oncotherapy pegged with an ‘Outperform’ rating and a price target of 155p, a premium of over 255% on its current share price of 43.5p.

With a current market cap of £55.9mln, the broker is targeting a potential value of around £143mln.

View full AVO profile View Profile

Advanced Oncotherapy PLC Timeline

Article
September 28 2018

Related Articles

cells
July 30 2018
Life science generally is developing at an incredible speed, says Joe Anderson
Widecells
September 27 2018
WideCells has undertaken a review of the business to deliver a strategy that will generate revenue, reduce overheads and achieve profitability
scientist looking through microscope
April 11 2018
Kumaraguru Raja sees “multiple catalysts” in the year ahead which could put a rocket under the share price

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright © Proactiveinvestors.com, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use